140 related articles for article (PubMed ID: 37467968)
1. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy.
Forlani G; Shallak M; Gatta A; Shaik AKB; Accolla RS
Biomed J; 2023 Oct; 46(5):100631. PubMed ID: 37467968
[TBL] [Abstract][Full Text] [Related]
2. The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins.
León Machado JA; Steimle V
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499042
[TBL] [Abstract][Full Text] [Related]
3. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.
Forlani G; Shallak M; Ramia E; Tedeschi A; Accolla RS
Retrovirology; 2019 Nov; 16(1):34. PubMed ID: 31783769
[TBL] [Abstract][Full Text] [Related]
4. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
5. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.
Bhat KP; Truax AD; Brooks JK; Greer SF
Immunol Cell Biol; 2010; 88(8):807-16. PubMed ID: 20351748
[TBL] [Abstract][Full Text] [Related]
6. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
8. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
9. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
10. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.
Forlani G; Abdallah R; Accolla RS; Tosi G
Front Microbiol; 2013; 4():234. PubMed ID: 23986750
[TBL] [Abstract][Full Text] [Related]
11. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.
Lee YS; Kim SH; Cho JA; Kim CW
Exp Mol Med; 2011 May; 43(5):281-90. PubMed ID: 21464590
[TBL] [Abstract][Full Text] [Related]
12. Expression of MHC II genes.
Drozina G; Kohoutek J; Jabrane-Ferrat N; Peterlin BM
Curr Top Microbiol Immunol; 2005; 290():147-70. PubMed ID: 16480042
[TBL] [Abstract][Full Text] [Related]
13. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
[TBL] [Abstract][Full Text] [Related]
14. Adenosine signaling inhibits CIITA-mediated MHC class II transactivation in lung fibroblast cells.
Fang M; Xia J; Wu X; Kong H; Wang H; Xie W; Xu Y
Eur J Immunol; 2013 Aug; 43(8):2162-73. PubMed ID: 23681904
[TBL] [Abstract][Full Text] [Related]
15. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
[TBL] [Abstract][Full Text] [Related]
16. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter.
Chen H; Gilbert CA; Hudson JA; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Feb; 44(6):1461-70. PubMed ID: 16765445
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
18. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.
Zhao M; Flynt FL; Hong M; Chen H; Gilbert CA; Briley NT; Bolick SC; Wright KL; Piskurich JF
Mol Immunol; 2007 Apr; 44(11):2923-32. PubMed ID: 17300840
[TBL] [Abstract][Full Text] [Related]
19. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
